National and Kapodistrian University of Athens
Study of the pleiotropic effect of anticoagulant treatment in critically ill patients
Abstract
dc:descriptionBackground: Despite advancements in mechanical ventilation protocols, fluid resuscitation and antibiotic treatment and maintenance of homeostatic blood glucose, survival rates in the Intensive Care Units still remain unacceptably low. Sepsis is a major cause of high mortality among critically ill patients. The basic pathophysiology of sepsis is characterized by interaction between coagulation and inflammation. Therefore, agents that ameliorate both may improve outcome. Heparin is such an agent, since, beyond the well – known anticoagulant property, it also exerts immunomodulatory, glycocalyx – protective activity. In fact, the range of the pleiotropic effect of heparin is so wide, that characterizing it solely as an anticoagulant is an underestimation, since it possesses tissue – protective, neuro – protective, nephro – protective, cardiovascular – protective properties and they further exert anti – cancer and anti – metastatic activity, anti – atherosclerotic activity and finally, anti – inflammatory and anti – hepcidin activity. Its strong anti – hepcidin effect is a subject of study that has only just recently been investigated during the past decade, albeit not adequately among humans, even more so among critically ill patients. Hepcidin is the basic regulator of iron homeostasis. The three main sources providing iron bioavailability are dietary absorption, red blood cell recycling and body iron reserve and, even though it is essential for life, it’s also potentially toxic. Excessive hepcidin results to iron decrease, noticed in Iron Refractory Iron Deficiency Anemia, as well as Anemia of Inflammation (or Anemia of Chronic Disease), common in a non-negligible number of degenerative diseases. Heparin’s anti – hepcidin activity seems highly dependent on a high molecular weight. We therefore hypothesized that unfractionated heparin, with its high molecular weight, would effectively repress hepcidin expression amongst critically ill patients. To the best of our knowledge, this is the first study to be conducted on humans.Aim – Objective: To determine whether unfractionated heparin leads to decrease of hepcidin levels in critically ill patients.Design: Prospective, non-invasive, observational study, conducted over the course of October 2017 and December 2019.Setting: A 10-bed Intensive Care Unit (ICU) of the 1st Department of Respiratory Medicine, Sotiria Thoracic Diseases HospitalParticipants: 22 critically ill patients, out of which 16 septic. Inclusion criteria were a hospitalization of at least 5-day duration and administration of unfractionated heparin, prescribed only at the attending physician’s discretion for any reason.Exposures: Administration of unfractionated heparin on the 1st, 2nd and 5th day of hospitalization.Main Outcomes and Measures: Mean hepcidin levels were significantly reduced compared to baseline following the 1st day of heparin administration (p=0.003).Results: Mean patient age (SD) was 72.6 (9.6) years and BMI was 30.1 (6.7) kg/m². Median ICU length of stay was 13 (5.8 – 26,8) days (interquartile range). ICU mortality was 27.3 % (95% confidence interval 17.1 – 47.5) and mean APACHE II score on admission was 24.5 (9.8). Heparin displayed a strong independent negative association with hepcidin (p Conclusions and Relevance: The anti-hepcidin effect of heparins, which has been shown to rely on their molecular weight, was confirmed for the first time in a sample of humans. This may lead to future treatment methods of forms of anemia characterized by an excess of hepcidin, common amongst the critically ill.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vagionas, Dimitrios
- Βαγιωνάς, Δημήτριος
Subjects
dc:subject × 15Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52767